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Abstract Sulfatases undergo an unusual protein modification
leading to conversion of a specific cysteine residue into K-
formylglycine. This conversion is essential for catalytic activity.
In arylsulfatase A the K-formylglycine is generated inside the
endoplasmic reticulum at a late stage of protein translocation.
Using in vitro translation in the presence of transport-competent
microsomes we found that arylsulfatase B is also modified in a
similar way by the formylglycine-generating machinery. Mod-
ification depended on protein transport and on the correct
position of the relevant cysteine. Arylsulfatase A and B did not
compete for modification, as became apparent in co-expression
experiments. This could argue for an association of the
modification machinery with the protein translocation apparatus.
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1. Introduction
In eukaryotic sulfatases a K-formylglycine (FGly, 2-amino-
3-oxo-propanoic acid) is found at a position where the genes
encode a cysteine [1,2]. De¢ciency of the FGly is associated
with catalytic inactivity of the sulfatases, as is found in multi-
ple sulfatase de¢ciency, a rare inherited human lysosomal
storage disorder [1,3,4]. The FGly residue is part of the cata-
lytic site, as has been shown by crystallographic analysis of
two lysosomal sulfatases, arylsulfatase A (ASA) and arylsul-
fatase B (ASB) [5,6]. The aldehyde group of the FGly residue,
most likely in its hydrated form [5,7], serves as an acceptor for
sulfate during sulfate ester cleavage [5^7]. In acting as a gemi-
nal diol the FGly hydrate allows for e⁄cient ester hydrolysis
at the acidic pH of lysosomes. The catalytic mechanism in-
volves trans-esteri¢cation of the sulfate group from the sub-
strate to the ¢rst hydroxyl, from where it is eliminated due to
the presence of the second hydroxyl [5,7].
The FGly residue in ASA is generated by protein modi¢-
cation at a late stage of co-translational protein translocation
into the endoplasmic reticulum (ER), as could be shown by in
vitro synthesis and translocation of nascent ASA polypeptides
into canine pancreas microsomes [8]. The modi¢cation is di-
rected by a linear sequence of 16 residues surrounding the
cysteine to be modi¢ed [8]. This sequence includes an X-P-
S-R and an L/M-T-G-R/K tetrapeptide, which are located C-
terminal of the cysteine and which are conserved among all
human sulfatases [2,9].
Since in multiple sulfatase de¢ciency the activity of all
tested sulfatases was severely decreased, it is likely that the
microsomal modifying machinery acts on all newly synthe-
sized sulfatase polypeptides. So far nothing is known about
the modifying machinery and its components, which are sup-
posed to catalyze a two-step reaction involving an oxidation
of the thiol to a thioaldehyde group and a hydrolytic release
of H2S [1]. To establish whether all sulfatases are modi¢ed in
the ER and to qualify the in vitro translation/translocation
system as a biochemical means to characterize the modifying
machinery we determined in vitro the modi¢cation of ASB
and compared it to that of ASA.
2. Materials and methods
2.1. Site-directed mutagenesis
Mutagenesis of a cDNA coding for human ASB [10] was carried
out by the QuikChange method (Stratagene) using complementary
primers (coding sequence GTGCTCCTGGACATGTACTACACG-
CAG) that substituted the Asn codon 84 by a methionine codon.
Inversion of codon 91 (Cys) and 92 (Thr) was achieved by PCR using
a non-coding primer (CTGGTAGCGGCCAGTGAGCAGCTGG-
CTCCGCGACGGGCAGGTCAGCGGCTGCG) covering the near-
by XcmI site. The PCR product was subcloned as a HindIII/XcmI
fragment replacing the corresponding fragment of the template
DNA pRL2 (see below). No Pfu- or Taq-polymerase errors were
detected upon sequencing of the entire coding sequences.
2.2. Protein expression and puri¢cation
The cDNAs of wild-type ASB and ASB-N84M, respectively, were
cloned as BamHI/EcoRI fragments into the pMPSVHE vector [11]
downstream of the myeloproliferative sarcoma virus promoter. The
resulting plasmid and PGK-hygro as selection marker were used for
stable transfection of mouse embryonic ¢broblasts de¢cient in both
mannose 6-phosphate receptors, as described [12]. The expresssed
ASB protein was puri¢ed from the secretions of the cells by a⁄nity
chromatography [13]. The speci¢c activity of both wild-type and mu-
tant enzyme was similar (about 100 U/mg). Synthesis of the ASB
proteins in an immature form (64 kDa), that due to constitutive se-
cretion from the mannose 6-phosphate receptor-de¢cient cells circum-
vent lysosomal processing [14], did not a¡ect the catalytic activity,
since mature ASB expressed in BHK cells had the same sulfatase
activity. The expressed proteins carried exclusively FGly and no cys-
teine in position 91, as was veri¢ed by mass spectrometry (see below).
Expression and puri¢cation of ASA-F59M protein was described ear-
lier [8].
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2.3. In vitro synthesis of ASB and ASA derivatives
The cDNA coding for residues 39^134 of ASB-N84M was ampli¢ed
by PCR using a coding primer (AATGCGGCTCCGGACGC-
CGGGGCCAGCCGGCCG), that added a BspEI site 5P to codon
39, and a non-coding primer (GAAGATCTTCTATTTTAGGAG-
CTGGGGCAGGA), that added a stop codon followed by a BglII
site 3P to codon 134. The PCR product was cloned as a BspEI/BglII
fragment into pTD3 [8] in frame with a sequence encoding the signal
peptide of preprolactin, thereby substituting the ASA sequences of
pTD3 [8]. In vitro expression of the resulting plasmid, designated
pRL2, and of the pTD3-derived plasmid pTD17 coding for ASA-
F59M, M85T, M87L, M120L (residues 19^200 fused to the signal
peptide of preprolactin, ref. [8]) was under control of the SP6-promo-
tor. Both translation products carried a single methionine in their
mature sequences (position 59 in ASA or position 84 in ASB).
In vitro synthesis of ASB- and ASA-derived proteins was carried
out in a coupled transcription/translation system (TNT, Promega), as
described [8]. Rough microsomes from dog pancreas [15] were added
at 7.5 equivalents [16] per 50 Wl translation mixture. For the co-ex-
pression experiment shown in Fig. 4 (lane 3) single translation reac-
tions expressing ASA or ASB, respectively, were mixed prior to in-
cubation at 30‡C. This 100 Wl sample was split into halves which both
were analyzed using either puri¢ed ASB-N84M or ASA-F59M protein
as a carrier (see below). Puri¢cation of translation products imported
by the microsomes using di¡erential centrifugation and proteinase K
digestion was described earlier [8]. Aliquots (2 Wl) were analyzed by
SDS-PAGE on high-Tris gels [8] and phosphorimaging (Figs. 1, 3 and
4). The remaining 48 Wl (98 Wl in the co-expression sample) were used
for peptide analysis.
2.4. Peptide analysis
Puri¢ed ASB (ASA) in vitro translation/translocation products
were mixed with 30^40 Wg of unlabeled ASB-N84M (ASA-F59M)
carrier protein and subjected to reductive carboxymethylation and
generation of peptides by trypsin or endoproteinase AspN, as de-
scribed [1,8]. Separation of peptides by RP-HPLC, mass spectrometry
and sequencing of peptides were also described earlier [1]. The proto-
cols for reaction of peptides with 2,4-dinitrophenylhydrazine and for
analysis of the peptide hydrazones are given in ref. [8].
3. Results
3.1. Modi¢cation of Cys-91 of ASB in the endoplasmic
reticulum
The FGly residue in human ASB is found in position 91 [1].
This position is equivalent to residue 69 of ASA, where a
cysteine that is encoded by the ASA gene is incorporated
into the primary translation product and becomes converted
into FGly upon translocation into microsomes [8]. In order to
analyze the presence or absence of FGly-91 in ASB synthe-
sized in vitro in the absence or presence of microsomes, we
expressed an N-terminal fragment of ASB-N84M comprising
residues 39^134 of ASB-N84M fused to the signal peptide of
preprolactin. The exchange of the authentic signal peptide
(residues 1^38) for that of preprolactin should ensure e⁄cient
translocation into the microsomes. To allow for incorporation
of a [35S]methionine-label during translation into the ASB
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Fig. 1. In vitro modi¢cation of ASB in the endoplasmic reticulum.
A: A fusion protein consisting of the signal peptide of preprolactin
and the N-terminal residues 39^134 of mature ASB-N84M was syn-
thesized in vitro in the presence of [35S]methionine and dog pan-
creas microsomes. The translation products were analyzed by SDS-
PAGE and phosphorimaging. The translation product imported into
and processed by the microsomes (mASB) was separated from the
non-imported precursor (pASB) by sedimentation of microsomes
(lane 1: supernatant; lane 2: pellet). pASB remaining unspeci¢cally
bound to the surface of microsomes (upper band in lane 2) was di-
gested by proteinase K and the proteolytic fragments were removed
by two further centrifugation steps leading to puri¢ed mASB (lane
3). The [35S]methionine is located in the tryptic peptide 3, as is
shown in the scheme. B: Radiolabeled mASB (about 20 nCi) was
mixed with 40 Wg of unlabeled ASB-N84M protein, serving as car-
rier, and subjected to reductive carboxymethylation, digestion with
trypsin and separation of its tryptic peptides by RP-HPLC. In the
chromatogram the position of the modi¢ed peptide 3 (P3*) is indi-
cated, as identi¢ed by mass spectrometry and N-terminal sequenc-
ing. The labeled peptide(s) were localized by liquid scintillation
counting (see histogram) and identi¢ed as derivative(s) of
[35S]peptide 3 by radiosequencing (not shown). The radioactive ma-
terial eluting in the fractions indicated by a horizontal bar, includ-
ing those containing P3* (indicated in black), was pooled, lyophi-
lized and digested with 0.2 Wg endoproteinase AspN in 50 mM
ammonium acetate (pH 8.0). C: Upon RP-HPLC of the resulting
peptides two radiolabeled peaks were obtained. The left peak (indi-
cated in black) coeluted with P3*C, which was identi¢ed by mass
spectrometry as indicated. D, E: By radiosequencing the two 35S-la-
beled peaks (see C) were identi¢ed as derivatives of [35S]peptide 3C
carrying [35S]methionine 84 in second position. The radioactivity re-
leased in each sequencing cycle is given as percentage of total radio-
activity recovered in the cleaved amino acids and the non-cleaved
material remaining on the sample ¢lter. D: N-terminal sequencing
of the left peak (see C) revealed the sequence DMYYT, which cor-
responds to residues 83^87 of P3*C. The presence of FGly 91 in
P3*C (residues 83^95) was veri¢ed by mass spectrometry (not
shown). E: Sequencing and mass spectrometry of the right peak
(see C) did not identify any amino acid or peptide signal. This is in
accordance with the presence of unmodi¢ed P3C in the in vitro
translation product and its absence in the carrier protein. Therefore
the sequence DMYYT is given in brackets.
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(39^134) fragment, which lacks methionines, Asn-84 was re-
placed by methionine. Expression of a full-length ASB-N84M
mutant in eukaryotic cells yielded a catalytically active protein
(see Section 2) indicating that substitution of Asn-84 by me-
thionine does not interfere with generation of FGly-91. This
could also be demonstrated by structural analysis of the ASB-
N84M protein (see below).
A cDNA encoding the preprolactin-ASB derivative de-
scribed above was subjected to coupled in vitro transcription
and translation in the presence of [35S]methionine and trans-
port-competent microsomes. The translation product im-
ported into and processed by the microsomes was puri¢ed
(mASB, Fig. 1A) and mixed with puri¢ed ASB-N84M protein
serving as carrier. This mixture was subjected to reductive
carboxymethylation of cysteines and tryptic digestion. Resi-
due 91 is part of the tryptic peptide 3 of ASB comprising
residues 69^95 (Fig. 1A). After separation of the tryptic pep-
tides by RP-HPLC one major 35S-labeled peak was recovered
(Fig. 1B). A part of the radioactivity coeluted with the FGly-
91 containing peptide 3 (designated P3*) of the ASB-N84M
carrier (Fig. 1B). The latter was identi¢ed by mass spectrom-
etry (2886 Da) and amino acid sequencing of the respective
fractions. The majority of the radioactivity eluted at a 1.0%
higher acetonitrile concentration, where the joined peptides 6
plus 7 (which lack methionines), but no peptide 3 of the ASB-
N84M carrier protein could be identi¢ed by sequencing and
mass spectrometry. Radiosequencing of this material revealed,
however, that a methionine was present in position 16, as
expected for peptide 3 of the in vitro translation product.
From experiments with ASA it is known that the peptide 2
carrying the cysteine to be modi¢ed elutes at a 1.5% higher
acetonitrile concentration than the FGly-containing form of
this peptide [1,8]. It was therefore likely that the majority of
the radiolabeled peptide of ASB-N84M represented the Cys-
91 containing form of peptide 3 (designated P3), which is
absent in wild-type ASB [1] and in the ASB-N84M carrier
(data not shown).
Due to the high hydrophobicity of the large peptide 3 RP-
HPLC did not lead to adequate separation of P3* and P3 to
allow quanti¢cation of modi¢cation. Therefore the fractions
containing the peak of radioactivity were pooled (see Fig. 1B)
and digested with endoproteinase AspN. This generates the
13-mer peptide 3C [1] comprising residues 83^95 of ASB-
N84M. By RP-HPLC the 35S-labeled peptide 3C could be
resolved in two forms (Fig. 1C). About 20% of the radioac-
tivity represented [35S]P3*C, as identi¢ed by its coelution with
carrier P3*C (mass: 1557 Da) and by radiosequencing (Fig.
1D). About 80% of the radioactivity did not coelute with a
carrier peptide, but by radiosequencing could be identi¢ed as
[35S]P3C (Fig. 1E).
To examine for the presence of an aldehyde function
[35S]P3C and [35S]P*3C were subjected to reaction with dini-
trophenylhydrazine (DNP-hydrazine) [8]. Only [35S]P3*C gave
rise to hydrazone formation which could be identi¢ed after
separation from non-reacted [35S]P3*C by RP-HPLC (Figs. 2
and 3, lane 2). The [35S]P3*C-DNP-hydrazone coeluted with
the unlabeled P3*C-DNP-hydrazone of the carrier, which had
the predicted mass of 1737 Da, i.e. 180 Da more than P3*C. It
should be noted that hydrazone formation of most FGly-con-
taining peptides is only partial. Quantitative hydrazone for-
mation was found only for smaller and more hydrophilic pep-
tides [8].
Taken together these data demonstrate that about 20% of
the ASB-N84M fragment synthesized in vitro carried a FGly
residue, when translation had been coupled to translocation
into microsomal membranes. In the absence of microsomes
the translation product representing the precursor form of
the preprolactin-ASB-N84M construct carried no aldehyde
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Fig. 3. Conversion of cysteine into FGly in ASB depends on import
into microsomes and on the correct position of the cysteine. The in
vitro translation/translocation product shown in lane 2, representing
the ASB construct shown in Fig. 1A, was analyzed for cysteine
modi¢cation as described in Figs. 1 and 2. The values given for
modi¢cation represent the percentage of [35S]P3*C of total [35S]P3C
recovered after HPLC of trypsin- and endoproteinase AspN-gener-
ated peptides (see Fig. 1C). In addition, the fraction of [35S]P3*C
that was converted into the corresponding DNP-hydrazone (see Fig.
2) is given. Lane 1 shows the results obtained after analysis of the
precursor form of the same ASB construct synthesized in the ab-
sence of microsomes. The apparent modi¢cation represents back-
ground radioactivity coeluting with unlabeled P3*C of the carrier
protein, since it did not react with DNP-hydrazine (see text). The
same holds true for the translation/translocation product shown in
lane 3, which was synthesized in the presence of microsomes but
carried the relevant cysteine in position 92 due to an inversion of
codons 91 (Cys) and 92 (Thr) in the cDNA.
Fig. 2. Presence of an aldehyde group in peptide 3C* after in vitro
translocation of ASB into microsomes. A: The [35S]methionine-la-
beled peptide 3*C coeluting with unlabeled P3*C (see Fig. 1C and
D) was tested for the presence of an aldehyde group by reaction
with DNP-hydrazine. The incubation mixture was subjected to RP-
HPLC in order to separate the DNP-hydrazone derivative from the
parent peptide and the reagent. The positions of P3*C and P3*C-
DNP-hydrazone are indicated, as identi¢ed by mass spectrometry.
The radioactivity pro¢le (see histogram) shows that [35S]P3*C was
also converted into the hydrazone with an e⁄ciency of approxi-
mately 40%. B: Reaction of [35S]P3C (see Fig. 1C and E) did not
give rise to DNP-hydrazone formation.
T. Dierks et al./FEBS Letters 423 (1998) 61^65 63
group (pASB; Fig. 3, lane 1). The labeled material coeluting
with P3*C of the carrier protein (9% of P3C-associated radio-
activity) did not react with DNP-hydrazine and represented
contaminating radioactivity. This background was rather
high, since the crude translation product present in the retic-
ulocyte lysate had to be analyzed.
The speci¢city of the modifying machinery was tested by
inverting the position of the cysteine to be modi¢ed and the
position of its C-terminal neighbor (threonine 92). After
translation and import of this ASB-mutant into microsomes
peptide analysis revealed that only some background radio-
activity (6% of P3C-associated radioactivity) coeluted with
P3*C of the carrier protein (Fig. 3, lane 3). This radioactive
material did not react with DNP-hydrazine.
3.2. Simultaneous modi¢cation of ASA and ASB
The relative e⁄ciencies of in vitro modi¢cation of ASB and
ASA, quantitated as percentage of ASB-[35S]P3*C or ASA-
[35S]P2*, respectively, of total [35S]P3C or [35S]P2, respec-
tively, were very similar when assayed in parallel (Fig. 4, lanes
1 and 2). We wanted to know whether the modi¢cation e⁄-
ciency of ASA and/or ASB is a¡ected when the two sulfatases
are translated and translocated simultaneously. When co-ex-
pressed in the presence of microsomes, ASA and ASB were
translated and translocated with the same e⁄ciency, as com-
pared to the single expression controls (Fig. 4, lane 3; it
should be noted that the aliquot subjected to SDS-PAGE in
lane 3 is only 50% of that applied in lanes 1 and 2). Analysis
of the tryptic peptides of these translocation products, which
in the case of ASB had to be digested additionally with endo-
proteinase AspN (see Fig. 1), clearly showed a similar extent
of modi¢cation in the co-expressed sulfatases as in the singly
expressed ASA or ASB. If changed at all, a slight increase of
relative modi¢cation was observed for both ASA and ASB
(Fig. 4). Calculation of total radioactivity recovered in the
HPLC fractions associated with the modi¢ed peptides of
ASA and ASB revealed that similar amounts of molecules
had been modi¢ed per equivalent of microsomes [16] in all
three samples shown in Fig. 4.
4. Discussion
ASB is subjected to FGly formation in the ER by a mech-
anism that shares all characteristics observed earlier for ASA
[8]. FGly formation depended on protein import into the ER
and on the presence of a cysteine in the primary translation
product located at the correct position within a sequence that
is highly conserved among eukaryotic sulfatases and obvi-
ously determines this novel protein modi¢cation (see Section
1). This supports the notion that most likely all eukaryotic
sulfatases are subjected to this modi¢cation by a common
modifying machinery located in the ER.
This machinery obviously is saturable under in vivo and in
vitro conditons [1,8]. For ASA it was shown in vitro that
reducing the expression to about one-twentieth of the level
used in the present and in an earlier study [8] doubles the
relative modi¢cation e⁄ciency from about 20% to about
40% [8]. Using the high expression conditions we observed a
similar modi¢cation e⁄ciency of about 20% for both ASA
and ASB. This e⁄ciency did not drop when ASA and ASB
were translocated simultaneously into microsomes. This may
indicate that the modi¢ying machinery has a similar a⁄nity
for ASA and ASB. However, several other observations are
inconsistent with this conclusion. In multiple sulfatase de¢-
ciency usually low residual activities of the various sulfatases
are detectable. This is attributed to a residual activity of the
modifying machinery. Characteristically the residual activity
of ASB is the highest among all sulfatases, e.g. 2^4 times
higher than that of ASA [17,18]. This suggests that in vivo
modi¢cation of ASB is more e⁄cient than that of other sul-
fatases. Accordingly, in recombinant ASB Cys-91 is quantita-
tively modi¢ed to FGly, while in recombinant ASA expressed
under similar conditions 10^40% of the Cys-69 escape mod-
i¢cation [1]. In contrast to these in vivo data the in vitro data
presented in this study would argue for a similar a⁄nity of the
modifying machinery for ASB and ASA. The similar and
overall rather low modi¢cation e⁄ciencies observed in the in
vitro system, however, may in fact result from limitation at a
certain step of modi¢cation that is not limiting in vivo. If the
translocation and modifying machineries are coupled at the
lumenal side of the ER membrane, limited modi¢cation may
merely re£ect an excess of translocation over modi¢cation
under in vitro conditions. Until now attempts to uncouple
translocation and modi¢cation, e.g. by studying modi¢cation
of a sulfatase precursor polypeptide in a microsomal detergent
extract, have proven unsuccessful (not shown). Obviously, the
translocation and modi¢cation machineries have to be co-re-
constituted in order to develop our in vitro system into an
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Fig. 4. Simultaneous modi¢cation of ASB and ASA. The ASB-
N84M construct shown in Fig. 1A (mASB) and the ASA-F59M
construct (mASA, see Section 2) were translated and imported into
microsomes, each in a 50-Wl reaction mixture (lanes 1 and 2). In ad-
dition, duplicates of these translation reactions were mixed prior to
incubation at 30‡C (lane 3). The phosphorimaging shows 2-Wl ali-
quots of the import products puri¢ed from each translation reaction
(i.e. 4% of total in lanes 1 and 2, but only 2% in lane 3) indicating
that the two sulfatases are translated and translocated without af-
fecting each other. Note that both mASA and mASB contain a sin-
gle [35S]methionine. The puri¢ed import products were analyzed for
the presence of the FGly-containing peptides P3*C (ASB) or P2*
(ASA), respectively. The import products puri¢ed from the 100-Wl
coexpression sample were analyzed in duplicate. One half was mixed
with ASB-N84M carrier protein, the other half with ASA-F59M
carrier protein. Analysis of the 35S-labeled tryptic peptides in a sin-
gle RP-HPLC run was possible, since the tryptic peptides 2 of ASA
and 3 of ASB elute at well separated positions in the acetonitrile
gradient. The modi¢cation e⁄ciency of ASB was calculated as de-
scribed in Fig. 3. For ASA the radioactivity coeluting from the RP-
column with the tryptic P2* of the carrier ASA-F59M protein and
giving a positive reaction with DNP-hydrazine was quantitiated (see
[8]).
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assay that is suitable to biochemically identify the modifying
enzyme(s).
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